Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/16—Masculine contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/18—Feminine contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

• This invention relates to a dosage regimen for emergency contraception, to pharmaceutical compositions of the same purpose, the use of levonorgestrel for the manufacture of pharmaceutical compositions for the same purpose, as well as the process of manufacturing these pharmaceutical compositions.
• Norgestrel and levonorgestrel namely the D isomer of norgestrel [+-17 ⁇ -13-ethyl-17- hydroxy-18,19-dinorpregn-4-en-20-in-3-on] have been used in combined preparations as contraceptives for a long time.
• a pharmaceutical composition called OVRAL which appeared in 1968 and contained 0.05 mg of ethynyl-estradiol and 0.5 mg of norgestrel.
• the British patent No 1,041,280 describes the preparation of tablets, capsules and suspension of anabolic activity containing 5 mg of norgestrel as active ingredient, although in the description of the biological activity of the active ingredient the estrogen antagonist activity is said to be 53.7-fold compared to that of the progesterone and the progestogen activity is the same as that of the progesterone.
• the object of this invention is a dosage regimen for emergency contraception and a pharmaceutical composition for the application of this regimen.
• the regimen according to this invention is that a single dose containing only 1.5 + 0.2 mg of levonorgestrel as active ingredient is administered to women to be treated with a pharmaceutical composition within 72 hours of unprotected coitus. Further objects of this invention are the dosage units required to carry out the above regimen.
• the dosage units required to carry out the above regimen can be in solid or liquid state, and they can be for example tablets, film-coated tablets, coated tablets, capsules, pills or powder preparations.
• Liquid compositions can be for example solutions for injection or infusion.
• Tablets of 100 mg total weight are prepared from the following ingredients for each tablet: levonorgestrel 1.5 mg hydrophilic colloidal silicium dioxide 0.5 mg maize-starch 23.5 mg potato-starch 0.5 mg talcum 2.5 mg magnesium stearate 1.0 mg lactose monohydrate 70.5 mg
• the tablets of the above composition are prepared by homogenization of the calculated quantity of the active ingredient into the powder mixture of lactose monohydrate and maize- starch, or spraying the solution of it in alcohol and/or in a mixture of alcohol : chloroform onto the above powder mixture of lactose and maize-starch (forming the inner phase) in a fluidization granulation equipment.
• the granulating liquid prepared from a part of the maize-starch is sprayed into the mixture and the fluid bed is solidified with streaming air.
• the granulation takes place parallel with the drying.
• the obtained grains are regranulated if necessary, hydrophilic colloidal silicium dioxide, the talcum and the magnesium stearate (forming the outer phase) are admixed, then tablets are pressed from the homogenous mixture.
• Example 2 Tablets of 100 mg total weight are prepared from the following ingredients for each tablet: levonorgestrel 1.5 mg hydrophilic colloidal silicium dioxide 0.5 mg talcum 0.5 mg magnesium stearate 1.0 mg polivinyl-pirrolidon (Polivinodum K-30) 2.5 mg croscarmellose sodium 4.0 mg lactose monohydrate 40.0 mg macrocrystalline cellulose 50.0 mg
• the tablets of the above given composition are prepared by homogenization of the calculated quantity of the active ingredient into the powder mixture of lactose monohydrate and microcrystalline cellulose, or spraying the solution of it in alcohol and/or in a mixture of alcohol : chloroform onto the above powder mixture of lactose and microcrystalline cellulose (forming the inner phase) in a kneading granulation equipment.
• the granulating liquid prepared from PVP-K30 is added and the product is granulated by kneading.
• the wet granulates are regranulated, and dried in a microwave vacuum dryer or in a fluidization equipment.
• Croscarmellose sodium, hydrophilic colloidal silicium dioxide, talcum and magnesium stearate (forming in the outer phase) are mixed to the above granulates, then 100 mg tablets are pressed from the homogenous mixture.
• Example 3 Tablets of 100 mg total weight are prepared from the following ingredients for each tablet: levonorgestrel 1.5 mg microcrystalline cellulose 50.0 mg hydrophilic colloidal silicium dioxide 0.5 mg pregelatinized starch 4.0 mg ultra amolipectine 3.0 mg magnesium stearate 1.0 mg lactose monohydrate 40.0 mg
• composition of powder mixture is homogenized with the exception of magnesium stearate in a tank or in a container homogenizer, then magnesium stearate is added and the powder mixture is end-homogenized. Then 100 mg tablets are pressed from the homogenous powder mixture.

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Endocrinology (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Reproductive Health (AREA)
• Gynecology & Obstetrics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Steroid Compounds (AREA)

Priority Applications (23)

Applications Claiming Priority (2)

Publications (1)

Family

ID=89998939

Family Applications (1)

Country Status (33)

Cited By (6)

Families Citing this family (19)

• 2001
  • 2001-11-27 HU HU0105173A patent/HU227198B1/hu unknown
• 2002
  • 2002-11-26 EP EP02783334A patent/EP1448207B1/en not_active Expired - Lifetime
  • 2002-11-26 AP APAP/P/2004/003046A patent/AP1849A/en active
  • 2002-11-26 NZ NZ530056A patent/NZ530056A/en not_active IP Right Cessation
  • 2002-11-26 PL PL369520A patent/PL206010B1/pl unknown
  • 2002-11-26 RS YUP-42/04A patent/RS50768B/sr unknown
  • 2002-11-26 BR BR0210595-0A patent/BR0210595A/pt not_active Application Discontinuation
  • 2002-11-26 MX MXPA04005104A patent/MXPA04005104A/es active IP Right Grant
  • 2002-11-26 HR HR20040584 patent/HRP20040584B1/xx not_active IP Right Cessation
  • 2002-11-26 WO PCT/HU2002/000129 patent/WO2003045397A1/en not_active Ceased
  • 2002-11-26 AU AU2002347401A patent/AU2002347401A1/en not_active Abandoned
  • 2002-11-26 DK DK02783334T patent/DK1448207T3/da active
  • 2002-11-26 OA OA1200400148A patent/OA12730A/fr unknown
  • 2002-11-26 GE GE5567A patent/GEP20063882B/en unknown
  • 2002-11-26 KR KR1020047002069A patent/KR100908161B1/ko not_active Expired - Lifetime
  • 2002-11-26 AT AT02783334T patent/ATE293978T1/de active
  • 2002-11-26 PT PT02783334T patent/PT1448207E/pt unknown
  • 2002-11-26 UA UA20040504015A patent/UA79942C2/uk unknown
  • 2002-11-26 CN CNA028137523A patent/CN1551774A/zh active Pending
  • 2002-11-26 DE DE60203929T patent/DE60203929T2/de not_active Expired - Lifetime
  • 2002-11-26 CA CA2450359A patent/CA2450359C/en not_active Expired - Lifetime
  • 2002-11-26 EA EA200400731A patent/EA006545B1/ru unknown
  • 2002-11-26 IL IL15939402A patent/IL159394A0/xx unknown
  • 2002-11-26 ES ES02783334T patent/ES2239727T3/es not_active Expired - Lifetime
  • 2002-11-26 SI SI200230132T patent/SI1448207T1/xx unknown
  • 2002-11-26 JP JP2003546899A patent/JP2005516904A/ja not_active Withdrawn
• 2003
  • 2003-12-05 IS IS7065A patent/IS2691B/is unknown
• 2004
  • 2004-03-26 TN TNP2004000048A patent/TNSN04048A1/en unknown
  • 2004-04-20 NO NO20041607A patent/NO333984B1/no not_active IP Right Cessation
  • 2004-04-21 MA MA27643A patent/MA27076A1/fr unknown
  • 2004-05-26 ZA ZA2004/04114A patent/ZA200404114B/en unknown
  • 2004-06-25 EC EC2004005171A patent/ECSP045171A/es unknown
  • 2004-10-05 US US10/495,923 patent/US20050288264A2/en not_active Abandoned

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events